Vitamin D Supplementation for Multiple Sclerosis
Based on the most recent high-quality evidence, vitamin D supplementation does not reduce disease activity or relapse rates in established multiple sclerosis, though it may have modest benefits in very early disease (clinically isolated syndrome). The 2018 ESPEN neurology guideline explicitly states that vitamin D supplementation should not be recommended to decrease relapses in MS patients 1.
Evidence Quality and Recommendations
The strongest recent evidence comes from three major randomized controlled trials:
- D-Lay MS (2025): High-dose vitamin D (100,000 IU every 2 weeks) in clinically isolated syndrome showed reduced MRI activity but no significant reduction in clinical relapses 2
- VIDAMS (2023): High-dose vitamin D (5000 IU/day) versus low-dose (600 IU/day) showed no difference in relapse rates in established RRMS 3
- Australian/New Zealand trial (2024): No dose of vitamin D (1000,5000, or 10,000 IU daily) prevented conversion from CIS to definite MS 4
The 2018 ESPEN guideline reviewed multiple RCTs and meta-analyses and found no evidence supporting vitamin D supplementation for reducing MS disease activity 1. This represents the most authoritative guidance specific to MS.
Practical Approach for MS Patients
For General Bone Health (Not MS Disease Modification)
Since MS patients are at increased risk for osteoporosis and vitamin D deficiency:
Measure baseline 25(OH)D levels 5:
- Target range: 30-50 ng/mL (75-125 nmol/L) for bone health
- Upper safety limit: 100 ng/mL
If 25(OH)D < 30 ng/mL, use correction phase 5:
- 50,000 IU weekly for 8 weeks, then
- Maintenance: 800-2000 IU daily
If 25(OH)D ≥ 30 ng/mL, maintenance supplementation 5:
- 800-2000 IU daily (standard adult dose)
Monitoring Strategy
- Recheck 25(OH)D after 3 months of supplementation 5
- Avoid annual high-dose boluses (500,000 IU) - associated with adverse outcomes 5
- Prefer daily or weekly dosing over large intermittent doses
Special Considerations for MS Patients
Patients on medications affecting vitamin D metabolism (anticonvulsants, glucocorticoids) may require 2-3 times higher doses (6000-10,000 IU daily) 6.
Obese patients similarly require higher doses to achieve target levels 6.
Critical Caveats
Do not prescribe high-dose vitamin D with the expectation of modifying MS disease activity. While observational studies suggested associations between vitamin D levels and MS outcomes, multiple high-quality RCTs have failed to demonstrate clinical benefit 1, 7, 3. The 2018 ESPEN guideline explicitly recommends against this practice 1.
The only potential exception is very early disease (CIS within 90 days), where the D-Lay MS trial showed reduced MRI activity with 100,000 IU every 2 weeks, though clinical relapse rates were not significantly different 2. This requires further validation before routine recommendation.
Safety monitoring: While doses up to 10,000 IU daily are generally safe, monitor for hypercalcemia in patients with conditions causing extrarenal 1,25(OH)₂D production, and check calcium levels if using very high doses 6.
Bottom Line Algorithm
- Measure 25(OH)D level in all MS patients
- If deficient (< 30 ng/mL): Correct with 50,000 IU weekly × 8 weeks
- Maintenance: 800-2000 IU daily for bone health
- Target level: 30-50 ng/mL (not higher for MS-specific benefits)
- Recheck at 3 months, then annually or as clinically indicated
- Do not use vitamin D as MS disease-modifying therapy - continue appropriate disease-modifying drugs as primary treatment